About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Pfizer Paid for Doc's Helicopter in Off-Label Geodon Push, Suit Claims

By Jim Edwards | Sep 17, 2009

Pfizer paid a doctor $4,000 a day to promote the antipsychotic Geodon and expensed his use of a private helicopter to get to off-label speaking events, according a whistleblower lawsuit that was part of the $2.3 billion Bextra settlement.

Pfizer said in a statement:

Pfizer denies all federal, state and qui tam allegations, with two exceptions. We acknowledge certain improper actions related to the past promotion of Bextra and Zyvox. Beyond those two exceptions we deny all federal and state and qui tam claims.

The suit was brought by Mark R. Westlock of Fenton, Mo., was a rep for Pfizer from 1991 to 2007, when he claims he was forced to resign. (Download Westlock v. Pfizer here.) He alleges that Dr. Neil S. Kaye of Wilmington, Del., an assistant clinical professor of psychiatry at Jefferson Medical College, received $4,000 a day in speaker fees to talk to other doctors about “the off label use of Geodon® in adolescents,” among other issues. He was used so frequently by Pfizer that he was flown  by ‘copter to some of his gigs, Westlock claims:

(Click to enlarge.)

The top image is from Kaye’s own website. He details his interest in helicopters here and here and here.

Some of Kaye’s material was sent to Pfizer pharmaceutical sales representatives under the heading “take home selling points.” The material within that package was also labelled “do not detail,” ostensibly because it covered off-label material. But Westlock claims that everyone knew they were to use it in their sales pitches because the email would not have been titled “take home selling points” if they were not in fact selling points.


Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • M.D. pilot made off-label Pfizer rounds

    FiercePharma - 144 days 11 hours 17 minutes ago

    A penchant for helicopters characterizes forensic psychiatrist Neil Kaye, M.D., a prominent player in the recent $2.3 billion Pfizer off-label marketing settlement. According to Bnet, high-roller Kaye allegedly received $4,000 a day to promote Geodon, an antipsychotic drug, in addition to expense reimbursement for use of his own helicopter to...

  • Pharma Whistleblowing: How It Works

    In the Pipeline - 158 days 6 hours 43 minutes ago

    Here's more detail on the case that led to Pfizer's 2.3 billion dollar fine/settlement, courtesy of Bloomberg. Here's how things got started, apparently: Nor did he go for the so-called off-label uses they suggested, such as treating dementia in the elderly. Kruszewski didn’t just say no. He went and checked the research and saw Geodon could...

  • Pfizer's $2.3B promise to behave

    FiercePharma - 159 days 10 hours 43 minutes ago

    Back in January, Pfizer set aside $2.3 billion to settle a Justice Department investigation. Word was that it dealt with improper Bextra marketing. But the reality is that, while Bextra infractions headline the deal, it also involves several other drugs, including the psychiatric drug Geodon, the zntibiotic Zyvox, and the epilepsy remedy Lyrica....

  • Federal Prosecutor Warns Drug Companies on Off-Label Promotion: "This Must Stop"

    BNET Pharma - 378 days 5 hours 23 minutes ago

    Laurie Magid, the acting U.S. attorney for Pennsylvania's Eastern District, has written a strongly worded warning to drug companies that they must stop promoting off-label uses for drugs or face the consequences. The warning comes after both Pfizer and Eli Lilly paid record fines for off-label promotion of Zyprexa and Bextra, respectively. Lilly...

  • Why the upsurge in False Claims Act cases against pharmaceutical companies for off-label promotion?

    PharmaGossip - 147 days 10 hours 14 minutes ago

    Lax Food and Drug Administration (FDA) enforcement of its own regulations. That’s the take of Brian Kenney of Kenney Egan in Philadelphia. Kenney last week settled part of the massive $2.3 billion False Claims Act case against Pfizer for off-label promotion of its drugs. Kenney represented Harrisburg psychiatrist, Dr. Stefan Kruszewski ....

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)